Abstract
Objective: Utilizing cytology specimens for molecular testing has attracted increasing attention in the era of personalized medicine. Cytology specimens are clinically easier to access. The samples can be quickly and completely fixed in a very short time of fixation before tissue degradation occurs, compared to hours or days of fixation in surgical pathology specimens. In addition, cytology specimens can be fixed without formalin, which can significantly damage DNA and RNA. All these factors contribute to the superb quality of DNA and RNA in cytology specimens for molecular tests. Study Design: We summarize the most pertinent information in the literature regarding molecular testing in the field of cytopathology. Results: The first part focuses on the types of cytological specimens that can be used for molecular testing, including the advantages and limitations. The second section describes the common molecular tests and their clinical application. Conclusion: Various types of cytology specimens are suitable for many molecular tests, which may require additional clinical laboratory validation.
References
1.
Rekhtman
N
, Roy-Chowdhuri
S
. Cytology Specimens: A Goldmine for Molecular Testing
. Arch Pathol Lab Med
. 2016
Nov
;140
(11
):1189
–90
.
[PubMed]
0003-99852.
Wei
S
, Lieberman
D
, Morrissette
JJ
, Baloch
ZW
, Roth
DB
, McGrath
C
. Using “residual” FNA rinse and body fluid specimens for next-generation sequencing: an institutional experience
. Cancer Cytopathol
. 2016
May
;124
(5
):324
–9
.
[PubMed]
1934-662X3.
VanderLaan
PA
. Molecular markers: implications for cytopathology and specimen collection
. Cancer Cytopathol
. 2015
Aug
;123
(8
):454
–60
.
[PubMed]
1934-662X4.
Warth
A
, Penzel
R
, Brandt
R
, Sers
C
, Fischer
JR
, Thomas
M
, et al Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies
. Virchows Arch
. 2012
Apr
;460
(4
):407
–14
.
[PubMed]
0945-63175.
Jain
D
, Roy-Chowdhuri
S
. Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review
. Arch Pathol Lab Med
. 2018
Sep
;142
(9
):1127
–33
.
[PubMed]
0003-99856.
de Biase
D
, Visani
M
, Malapelle
U
, Simonato
F
, Cesari
V
, Bellevicine
C
, et al Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy)
. PLoS One
. 2013
Dec
;8
(12
):e83607
.
[PubMed]
1932-62037.
Rekhtman
N
, Buonocore
DJ
, Rudomina
D
, Friedlander
M
, Dsouza
C
, Aggarwal
G
, et al Novel Modification of HistoGel-Based Cell Block Preparation Method: Improved Sufficiency for Molecular Studies
. Arch Pathol Lab Med
. 2018
Apr
;142
(4
):529
–35
.
[PubMed]
0003-99858.
Hopkins
E
, Moffat
D
, Parkinson
I
, Robinson
P
, Jersmann
H
, Dougherty
B
, et al Cell block samples from endobronchial ultrasound transbronchial needle aspiration provide sufficient material for ancillary testing in lung cancer-a quaternary referral centre experience
. J Thorac Dis
. 2016
Sep
;8
(9
):2544
–50
.
[PubMed]
2072-14399.
Harada
S
, Agosto-Arroyo
E
, Levesque
JA
, Alston
E
, Janowski
KM
, Coshatt
GM
, et al Poor cell block adequacy rate for molecular testing improved with the addition of Diff-Quik-stained smears: need for better cell block processing
. Cancer Cytopathol
. 2015
Aug
;123
(8
):480
–7
.
[PubMed]
1934-662X10.
Gailey
MP
, Stence
AA
, Jensen
CS
, Ma
D
. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue
. Cancer Cytopathol
. 2015
Jan
;123
(1
):30
–9
.
[PubMed]
1934-662X11.
Crapanzano
JP
, Heymann
JJ
, Monaco
S
, Nassar
A
, Saqi
A
. The state of cell block variation and satisfaction in the era of molecular diagnostics and personalized medicine
. Cytojournal
. 2014
Mar
;11
(1
):7
.
[PubMed]
1742-641312.
Yung
RC
, Otell
S
, Illei
P
, Clark
DP
, Feller-Kopman
D
, Yarmus
L
, et al Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration
. Cancer Cytopathol
. 2012
Jun
;120
(3
):185
–95
.
[PubMed]
1934-662X13.
Lozano
MD
, Echeveste
JI
, Abengozar
M
, Mejías
LD
, Idoate
MA
, Calvo
A
, et al Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less
. Arch Pathol Lab Med
. 2018
Mar
;142
(3
):291
–8
.
[PubMed]
0003-998514.
Partyka
KL
, Randolph
ML
, Lawrence
KA
, Cramer
H
, Wu
HH
. Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: A comparison of two proprietary testing platforms
. Diagn Cytopathol
. 2018
Apr
;46
(4
):320
–5
.
[PubMed]
8755-103915.
Knoepp
SM
, Roh
MH
. Ancillary techniques on direct-smear aspirate slides: a significant evolution for cytopathology techniques
. Cancer Cytopathol
. 2013
Mar
;121
(3
):120
–8
.
[PubMed]
1934-662X16.
Wei
S
, Baloch
Z
, Gentile
C
, Shah
M
, Hiemenz
M
, Watt
C
: Diff-Quik (R) Stained Cytology Smear Slides as Primary or Supplemental Source for Molecular Analysis: LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA, 2015
, 95, pp 111A-111A.17.
Killian
JK
, Walker
RL
, Suuriniemi
M
, Jones
L
, Scurci
S
, Singh
P
, et al Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling
. J Mol Diagn
. 2010
Nov
;12
(6
):739
–45
.
[PubMed]
1525-157818.
Xu
W
, Khurana
KK
, Tull
J
, Maciak
C
, Zhang
S
. Destaining of Diff-Quik stained cytologic smears is not necessary for the detection of anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma by fluorescence in situ hybridization
. J Cytol
. 2016
Jul-Sep
;33
(3
):154
–8
.
[PubMed]
0970-937119.
Dejmek
A
, Zendehrokh
N
, Tomaszewska
M
, Edsjö
A
. Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality
. Cancer Cytopathol
. 2013
Jul
;121
(7
):344
–53
.
[PubMed]
1934-662X20.
Ozluk
Y
, Firat
P
, Yegen
G
, Hocaoglu
J
, Tas
S
, Yilmazbayhan
D
. EGFR mutation testing using archival-stained smears in non-small cell lung carcinoma
. Cytopathology
. 2017
Feb
;28
(1
):35
–45
.
[PubMed]
0956-550721.
Roy-Chowdhuri
S
, Chow
CW
, Kane
MK
, Yao
H
, Wistuba
II
, Krishnamurthy
S
, et al Optimizing the DNA yield for molecular analysis from cytologic preparations
. Cancer Cytopathol
. 2016
Apr
;124
(4
):254
–60
.
[PubMed]
1934-662X22.
Chen
S
, Randolph
M
, Cramer
HM
, Watkins
T
, McCullough
H
, Post
KM
, et al Detection of BRAF mutation in metastatic melanoma utilizing cell-transferred cytological smears
. Acta Cytol
. 2014
;58
(5
):478
–82
.
[PubMed]
0001-554723.
Gong
Y
, Joseph
T
, Sneige
N
. Validation of commonly used immunostains on cell-transferred cytologic specimens
. Cancer
. 2005
Jun
;105
(3
):158
–64
.
[PubMed]
0008-543X24.
da Cunha Santos
G
, Saieg
MA
, Troncone
G
, Zeppa
P
. Cytological preparations for molecular analysis: A review of technical procedures, advantages and limitations for referring samples for testing
. Cytopathology
. 2018
Apr
;29
(2
):125
–32
.
[PubMed]
0956-550725.
Fujii
T
, Asano
A
, Shimada
K
, Tatsumi
Y
, Obayashi
C
, Konishi
N
. Evaluation of RNA and DNA extraction from liquid-based cytology specimens
. Diagn Cytopathol
. 2016
Oct
;44
(10
):833
–40
.
[PubMed]
8755-103926.
Hwang
DH
, Garcia
EP
, Ducar
MD
, Cibas
ES
, Sholl
LM
. Next-generation sequencing of cytologic preparations: an analysis of quality metrics
. Cancer Cytopathol
. 2017
Oct
;125
(10
):786
–94
.
[PubMed]
1934-662X27.
Riker
AI
, Panelli
MC
, Kammula
US
, Wang
E
, Wunderlich
J
, Abati
A
, et al Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma
. Cancer Detect Prev
. 1999
;23
(5
):387
–96
.
[PubMed]
0361-090X28.
Mandry
P
, Murray
AB
, Höfler
H
. In situ hybridization of cytospin preparations: a rapid nonisotopic screening method for isolated cells
. Biotech Histochem
. 1994
May
;69
(3
):165
–70
.
[PubMed]
1052-029529.
Taketo
T
. Microspread ovarian cell preparations for the analysis of meiotic prophase progression in oocytes with improved recovery by cytospin centrifugation
. Methods Mol Biol
. 2012
;825
:173
–81
.
[PubMed]
1064-374530.
Santos
GC
, Saieg
MA
, Ko
HM
, Geddie
WR
, Boerner
SL
, Craddock
KJ
, et al Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation
. Cancer Cytopathol
. 2015
Jul
;123
(7
):413
–20
.
[PubMed]
1934-662X31.
Meiers
I
, Singh
H
, Hossain
D
, Lang
K
, Liu
L
, Qian
J
, et al Improved filter method for urine sediment detection of urothelial carcinoma by fluorescence in situ hybridization
. Arch Pathol Lab Med
. 2007
Oct
;131
(10
):1574
–7
.
[PubMed]
1543-216532.
Saieg
MA
, Geddie
WR
, Boerner
SL
, Liu
N
, Tsao
M
, Zhang
T
, et al The use of FTA cards for preserving unfixed cytological material for high-throughput molecular analysis
. Cancer Cytopathol
. 2012
Jun
;120
(3
):206
–14
.
[PubMed]
1934-662X33.
Peluso
AL
, Cascone
AM
, Lucchese
L
, Cozzolino
I
, Ieni
A
, Mignogna
C
, et al Use of FTA cards for the storage of breast carcinoma nucleic acid on fine-needle aspiration samples
. Cancer Cytopathol
. 2015
Oct
;123
(10
):582
–92
.
[PubMed]
1934-662X34.
Petras
ML
, Lefferts
JA
, Ward
BP
, Suriawinata
AA
, Tsongalis
GJ
. KRAS detection in colonic tumors by DNA extraction from FTA paper: the molecular touch-prep
. Diagn Mol Pathol
. 2011
Dec
;20
(4
):189
–93
.
[PubMed]
1052-955135.
Fuller
MY
, Mody
D
, Hull
A
, Pepper
K
, Hendrickson
H
, Olsen
R
. Next-Generation Sequencing Identifies Gene Mutations That Are Predictive of Malignancy in Residual Needle Rinses Collected From Fine-Needle Aspirations of Thyroid Nodules
. Arch Pathol Lab Med
. 2018
Feb
;142
(2
):178
–83
.
[PubMed]
0003-998536.
Sakairi
Y
, Sato
K
, Itoga
S
, Saegusa
F
, Matsushita
K
, Nakajima
T
, et al Transbronchial biopsy needle rinse solution used for comprehensive biomarker testing in patients with lung cancer
. J Thorac Oncol
. 2014
Jan
;9
(1
):26
–32
.
[PubMed]
1556-086437.
Reynolds
JP
, Zhou
Y
, Jakubowski
MA
, Wang
Z
, Brainard
JA
, Klein
RD
, et al Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples
. Cancer Cytopathol
. 2017
Mar
;125
(3
):178
–87
.
[PubMed]
1934-662X38.
Reynolds
JP
, Tubbs
RR
, Minca
EC
, MacNamara
S
, Almeida
FA
, Ma
PC
, et al EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC)
. Lung Cancer
. 2014
Nov
;86
(2
):158
–63
.
[PubMed]
0169-500239.
Petriella
D
, Galetta
D
, Rubini
V
, Savino
E
, Paradiso
A
, Simone
G
, et al Molecular profiling of thin-prep FNA samples in assisting clinical management of non-small-cell lung cancer
. Mol Biotechnol
. 2013
Jul
;54
(3
):913
–9
.
[PubMed]
1073-608540.
Deftereos
G
, Finkelstein
SD
, Jackson
SA
, Ellsworth
EM
, Krishnamurti
U
, Liu
Y
, et al The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions
. Mod Pathol
. 2014
Apr
;27
(4
):594
–601
.
[PubMed]
0893-395241.
Finkelstein
SD
, Bibbo
M
, Kowalski
TE
, Loren
DE
, Siddiqui
AA
, Solomides
C
, et al Mutational analysis of cytocentrifugation supernatant fluid from pancreatic solid mass lesions
. Diagn Cytopathol
. 2014
Aug
;42
(8
):719
–25
.
[PubMed]
8755-103942.
Finkelstein
SD
, Bibbo
M
, Loren
DE
, Siddiqui
AA
, Solomides
C
, Kowalski
TE
, et al Molecular analysis of centrifugation supernatant fluid from pancreaticobiliary duct samples can improve cancer detection
. Acta Cytol
. 2012
;56
(4
):439
–47
.
[PubMed]
0001-554743.
Brown
AE
, Lim
KS
, Corpus
G
, Hustek
MT
, Tran
TA
, Chang
CC
. Detection of BRAF mutation in the cytocentrifugation supernatant fluid from fine-needle aspiration of thyroid lesions may enhance the diagnostic yield
. Cytojournal
. 2017
Feb
;14
(1
):4
.
[PubMed]
1742-641344.
Roy-Chowdhuri
S
, Mehrotra
M
, Bolivar
AM
, Kanagal-Shamanna
R
, Barkoh
BA
, Hannigan
B
, et al Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling
. Mod Pathol
. 2018
Jul
;31
(7
):1036
–45
.
[PubMed]
0893-395245.
Butt
AN
, Swaminathan
R
. Overview of circulating nucleic acids in plasma/serum
. Ann N Y Acad Sci
. 2008
Aug
;1137
(1
):236
–42
.
[PubMed]
0077-892346.
Snyder
MW
, Kircher
M
, Hill
AJ
, Daza
RM
, Shendure
J
. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin
. Cell
. 2016
Jan
;164
(1-2
):57
–68
.
[PubMed]
0092-867447.
Wan
JC
, Massie
C
, Garcia-Corbacho
J
, Mouliere
F
, Brenton
JD
, Caldas
C
, et al Liquid biopsies come of age: towards implementation of circulating tumour DNA
. Nat Rev Cancer
. 2017
Apr
;17
(4
):223
–38
.
[PubMed]
1474-175X48.
Thierry
AR
, El Messaoudi
S
, Gahan
PB
, Anker
P
, Stroun
M
. Origins, structures, and functions of circulating DNA in oncology
. Cancer Metastasis Rev
. 2016
Sep
;35
(3
):347
–76
.
[PubMed]
0167-765949.
Jiang
P
, Lo
YM
. The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics
. Trends Genet
. 2016
Jun
;32
(6
):360
–71
.
[PubMed]
0168-952550.
Lo
YM
, Zhang
J
, Leung
TN
, Lau
TK
, Chang
AM
, Hjelm
NM
. Rapid clearance of fetal DNA from maternal plasma
. Am J Hum Genet
. 1999
Jan
;64
(1
):218
–24
.
[PubMed]
0002-929751.
Higgins
MJ
, Jelovac
D
, Barnathan
E
, Blair
B
, Slater
S
, Powers
P
, et al Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood
. Clin Cancer Res
. 2012
Jun
;18
(12
):3462
–9
.
[PubMed]
1078-043252.
Janku
F
, Angenendt
P
, Tsimberidou
AM
, Fu
S
, Naing
A
, Falchook
GS
, et al Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
. Oncotarget
. 2015
May
;6
(14
):12809
–21
.
[PubMed]
1949-255353.
Thierry
AR
, Mouliere
F
, El Messaoudi
S
, Mollevi
C
, Lopez-Crapez
E
, Rolet
F
, et al Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
. Nat Med
. 2014
Apr
;20
(4
):430
–5
.
[PubMed]
1078-895654.
Aung
KL
, Donald
E
, Ellison
G
, Bujac
S
, Fletcher
L
, Cantarini
M
, et al Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system
. J Mol Diagn
. 2014
May
;16
(3
):343
–9
.
[PubMed]
1525-157855.
Panka
DJ
, Buchbinder
E
, Giobbie-Hurder
A
, Schalck
AP
, Montaser-Kouhsari
L
, Sepehr
A
, et al Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma
. Mol Cancer Ther
. 2014
Dec
;13
(12
):3210
–8
.
[PubMed]
1535-716356.
Zill
OA
, Greene
C
, Sebisanovic
D
, Siew
LM
, Leng
J
, Vu
M
, et al Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
. Cancer Discov
. 2015
Oct
;5
(10
):1040
–8
.
[PubMed]
2159-827457.
Beaver
JA
, Jelovac
D
, Balukrishna
S
, Cochran
R
, Croessmann
S
, Zabransky
DJ
, et al Detection of cancer DNA in plasma of patients with early-stage breast cancer
. Clin Cancer Res
. 2014
May
;20
(10
):2643
–50
.
[PubMed]
1078-043258.
Bettegowda
C
, Sausen
M
, Leary
RJ
, Kinde
I
, Wang
Y
, Agrawal
N
, et al Shih l M, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA, Jr.: detection of circulating tumor DNA in early- and late-stage human malignancies
. Sci Transl Med
. 2014
;6
:224ra224
.1946-623459.
Bordi
P
, Del Re
M
, Danesi
R
, Tiseo
M
. Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer
. Transl Lung Cancer Res
. 2015
Oct
;4
(5
):584
–97
.
[PubMed]
2218-675160.
Reck
M
, Hagiwara
K
, Han
B
, Tjulandin
S
, Grohé
C
, Yokoi
T
, et al ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: the ASSESS Study
. J Thorac Oncol
. 2016
Oct
;11
(10
):1682
–9
.
[PubMed]
1556-086461.
Han
B
, Tjulandin
S
, Hagiwara
K
, Normanno
N
, Wulandari
L
, Laktionov
K
, et al EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study
. Lung Cancer
. 2017
Nov
;113
:37
–44
.
[PubMed]
0169-500262.
Dawson
SJ
, Tsui
DW
, Murtaza
M
, Biggs
H
, Rueda
OM
, Chin
SF
, et al Analysis of circulating tumor DNA to monitor metastatic breast cancer
. N Engl J Med
. 2013
Mar
;368
(13
):1199
–209
.
[PubMed]
0028-479363.
Tseng
JS
, Yang
TY
, Tsai
CR
, Chen
KC
, Hsu
KH
, Tsai
MH
, et al Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma
. J Thorac Oncol
. 2015
Apr
;10
(4
):603
–10
.
[PubMed]
1556-086464.
Oxnard
GR
, Paweletz
CP
, Kuang
Y
, Mach
SL
, O’Connell
A
, Messineo
MM
, et al Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
. Clin Cancer Res
. 2014
Mar
;20
(6
):1698
–705
.
[PubMed]
1078-043265.
Douillard
JY
, Ostoros
G
, Cobo
M
, Ciuleanu
T
, Cole
R
, McWalter
G
, et al Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status
. J Thorac Oncol
. 2014
Sep
;9
(9
):1345
–53
.
[PubMed]
1556-086466.
Van Emburgh
BO
, Sartore-Bianchi
A
, Di Nicolantonio
F
, Siena
S
, Bardelli
A
. Acquired resistance to EGFR-targeted therapies in colorectal cancer
. Mol Oncol
. 2014
Sep
;8
(6
):1084
–94
.
[PubMed]
1574-789167.
Su
KY
, Chen
HY
, Li
KC
, Kuo
ML
, Yang
JC
, Chan
WK
, et al Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer
. J Clin Oncol
. 2012
Feb
;30
(4
):433
–40
.
[PubMed]
0732-183X68.
Holderfield
M
, Deuker
MM
, McCormick
F
, McMahon
M
. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
. Nat Rev Cancer
. 2014
Jul
;14
(7
):455
–67
.
[PubMed]
1474-175X69.
Taniguchi
K
, Uchida
J
, Nishino
K
, Kumagai
T
, Okuyama
T
, Okami
J
, et al Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas
. Clin Cancer Res
. 2011
Dec
;17
(24
):7808
–15
.
[PubMed]
1078-043270.
Pereira
E
, Camacho-Vanegas
O
, Anand
S
, Sebra
R
, Catalina Camacho
S
, Garnar-Wortzel
L
, et al Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers
. PLoS One
. 2015
Dec
;10
(12
):e0145754
.
[PubMed]
1932-620371.
Ishii
H
, Azuma
K
, Yamada
K
, Kinoshita
T
, Imamura
Y
, Hoshino
T
. Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
. Oncol Lett
. 2014
Dec
;8
(6
):2699
–704
.
[PubMed]
1792-107472.
Thress
KS
, Brant
R
, Carr
TH
, Dearden
S
, Jenkins
S
, Brown
H
, et al EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
. Lung Cancer
. 2015
Dec
;90
(3
):509
–15
.
[PubMed]
0169-500273.
Chai
X
, Ren
P
, Wei
B
, Ma
J
, Mai
L
, Cram
DS
, et al A comparative study of EGFR oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinoma
. Clin Chim Acta
. 2016
Jun
;457
:106
–11
.
[PubMed]
0009-898174.
Seki
Y
, Fujiwara
Y
, Kohno
T
, Takai
E
, Sunami
K
, Goto
Y
, et al Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
. Oncologist
. 2016
Feb
;21
(2
):156
–64
.
[PubMed]
1083-715975.
Takahama
T
, Sakai
K
, Takeda
M
, Azuma
K
, Hida
T
, Hirabayashi
M
, et al Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
. Oncotarget
. 2016
Sep
;7
(36
):58492
–9
.
[PubMed]
1949-255376.
Bordi
P
, Tiseo
M
, Rofi
E
, Petrini
I
, Restante
G
, Danesi
R
, et al Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment
. Clin Lung Cancer
. 2017
Nov
;18
(6
):692
–7
.
[PubMed]
1525-730477.
He
J
, Tan
W
, Ma
J
. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer
. Future Oncol
. 2017
Apr
;13
(9
):787
–97
.
[PubMed]
1479-669478.
Wang
Z
, Cheng
G
, Han
X
, Mu
X
, Zhang
Y
, Cui
D
, et al Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma
. J Mol Diagn
. 2017
Jan
;19
(1
):169
–81
.
[PubMed]
1525-157879.
Mayo-de-Las-Casas
C
, Jordana-Ariza
N
, Garzón-Ibañez
M
, Balada-Bel
A
, Bertrán-Alamillo
J
, Viteri-Ramírez
S
, et al Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
. Ann Oncol
. 2017
Sep
;28
(9
):2248
–55
.
[PubMed]
0923-753480.
Balogh
Z
, Vielh
P
. Molecular tests use in cytological material (Analytical Phase). Molecular Applications in Cytology. Schmitt FC
. Switzerland
: Springer
; 2018
. pp. 29
–55
. 81.
Bluth
MJ
, Bluth
MH
. Molecular Pathology Techniques: advances in 2018
. Clin Lab Med
. 2018
Jun
;38
(2
):215
–36
.
[PubMed]
0272-271282.
Sokolova
IA
, Halling
KC
, Jenkins
RB
, Burkhardt
HM
, Meyer
RG
, Seelig
SA
, et al The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine
. J Mol Diagn
. 2000
Aug
;2
(3
):116
–23
.
[PubMed]
1525-157883.
Wang
W
, Tang
Y
, Li
J
, Jiang
L
, Jiang
Y
, Su
X
. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization
. Cancer Cytopathol
. 2015
Feb
;123
(2
):117
–22
.
[PubMed]
1934-662X84.
Neat
MJ
, Foot
NJ
, Hicks
A
, Breen
R
, Wilkins
B
, McLean
E
, et al ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer
. Cytopathology
. 2013
Dec
;24
(6
):356
–64
.
[PubMed]
0956-550785.
Minca
EC
, Lanigan
CP
, Reynolds
JP
, Wang
Z
, Ma
PC
, Cicenia
J
, et al ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material
. J Thorac Oncol
. 2014
Apr
;9
(4
):464
–8
.
[PubMed]
1556-086486.
Bozzetti
C
, Nizzoli
R
, Tiseo
M
, Squadrilli
A
, Lagrasta
C
, Buti
S
, et al ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients
. Diagn Cytopathol
. 2015
Nov
;43
(11
):941
–6
.
[PubMed]
8755-103987.
Rosenblum
F
, Hutchinson
LM
, Garver
J
, Woda
B
, Cosar
E
, Kurian
EM
. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma
. Cancer Cytopathol
. 2014
Nov
;122
(11
):810
–21
.
[PubMed]
1934-662X88.
Bluth
MJ
, Bluth
MH
. Molecular pathology techniques
. Clin Lab Med
. 2013
Dec
;33
(4
):753
–72
.
[PubMed]
0272-271289.
Bartley
PA
, Latham
S
, Budgen
B
, Ross
DM
, Hughes
E
, Branford
S
, et al A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia
. J Mol Diagn
. 2015
Mar
;17
(2
):185
–92
.
[PubMed]
1525-157890.
Park
KS
, Oh
YL
, Ki
CS
, Kim
JW
. Evaluation of the Real-Q BRAF V600E Detection Assay in Fine-Needle Aspiration Samples of Thyroid Nodules
. J Mol Diagn
. 2015
Jul
;17
(4
):431
–7
.
[PubMed]
1525-157891.
Morandi
L
, de Biase
D
, Visani
M
, Cesari
V
, De Maglio
G
, Pizzolitto
S
, et al Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation
. PLoS One
. 2012
;7
(4
):e36084
.
[PubMed]
1932-620392.
Takai
E
, Totoki
Y
, Nakamura
H
, Kato
M
, Shibata
T
, Yachida
S
. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer
. Adv Exp Med Biol
. 2016
;924
:13
–7
.
[PubMed]
0065-259893.
Santos
G
, Saieg
MA
. Molecular Techniques and methods applied in cytology. Molecular Cytopathology. Yang B, Rao J
. Switzerland
: Springer
; 2016
. pp. 16
–26
. 94.
Best
DH
, Dames
SA
, Wooderchak-Donahue
W
, Lewis
T
, Sumner
KL
, Vaughn
CP
, et al Molecular pathology methods. Molecular pathology in clinical practice. Leonard DG
. Switzerland
: Springer
; 2016
. pp. 19
–52
. 95.
Nikiforov
YE
, Ohori
NP
, Hodak
SP
, Carty
SE
, LeBeau
SO
, Ferris
RL
, et al Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples
. J Clin Endocrinol Metab
. 2011
Nov
;96
(11
):3390
–7
.
[PubMed]
0021-972X96.
McIver
B
, Castro
MR
, Morris
JC
, Bernet
V
, Smallridge
R
, Henry
M
, et al An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules
. J Clin Endocrinol Metab
. 2014
Nov
;99
(11
):4069
–77
.
[PubMed]
0021-972X97.
Pagan
M
, Kloos
RT
, Lin
CF
, Travers
KJ
, Matsuzaki
H
, Tom
EY
, et al The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes
. BMC Bioinformatics
. 2016
Jan
;17
(S1
Suppl 1
):6
.
[PubMed]
1471-210598.
Kloos
RT
, Barth
NM
. Gene Expression Classifier Testing and the Surgical Decision-Making Process for Patients With Thyroid Nodules
. JAMA Otolaryngol Head Neck Surg
. 2016
Aug
;142
(8
):806
–7
.
[PubMed]
2168-618199.
Harrison
G
, Sosa
JA
, Jiang
X
. Evaluation of the Afirma Gene Expression Classifier in Repeat Indeterminate Thyroid Nodules
. Arch Pathol Lab Med
. 2017
Jul
;141
(7
):985
–9
.
[PubMed]
0003-9985100.
Baca
SC
, Wong
KS
, Strickland
KC
, Heller
HT
, Kim
MI
, Barletta
JA
, et al Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes
. Cancer Cytopathol
. 2017
May
;125
(5
):313
–22
.
[PubMed]
1934-662X101.
Marti
JL
, Avadhani
V
, Donatelli
LA
, Niyogi
S
, Wang
B
, Wong
RJ
, et al Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules
. Ann Surg Oncol
. 2015
Nov
;22
(12
):3996
–4001
.
[PubMed]
1068-9265102.
Balentine
CJ
, Vanness
DJ
, Schneider
DF
. Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: considering the costs of surveillance
. Surgery
. 2018
Jan
;163
(1
):88
–96
.
[PubMed]
0039-6060103.
Pei
J
, Robu
V
, Feder
M
, Cheung
M
, Neumann-Domer
E
, Talarchek
J
, et al Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma
. Cancer Genet
. 2014
Mar
;207
(3
):98
–102
.
[PubMed]
2210-7762104.
Pei
J
, Feder
MM
, Al-Saleem
T
, Liu
Z
, Liu
A
, Hudes
GR
, et al Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma
. Genes Chromosomes Cancer
. 2010
Jul
;49
(7
):610
–9
.
[PubMed]
1045-2257105.
Tsiatis
AC
, Norris-Kirby
A
, Rich
RG
, Hafez
MJ
, Gocke
CD
, Eshleman
JR
, et al Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications
. J Mol Diagn
. 2010
Jul
;12
(4
):425
–32
.
[PubMed]
1525-1578106.
Young
EC
, Owens
MM
, Adebiyi
I
, Bedenham
T
, Butler
R
, Callaway
J
, et al; Clinical Molecular Genetics Society (CMGS) Scientific Subcommittee
. A comparison of methods for EGFR mutation testing in non-small cell lung cancer
. Diagn Mol Pathol
. 2013
Dec
;22
(4
):190
–5
.
[PubMed]
1052-9551107.
Vigliar
E
, Malapelle
U
, de Luca
C
, Bellevicine
C
, Troncone
G
. Challenges and opportunities of next-generation sequencing: a cytopathologist’s perspective
. Cytopathology
. 2015
Oct
;26
(5
):271
–83
.
[PubMed]
0956-5507108.
Liu
L
, Shao
D
, Deng
Q
, Tang
H
, Wang
J
, Liu
J
, et al Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens
. J Thorac Dis
. 2018
May
;10
(5
):2631
–7
.
[PubMed]
2072-1439109.
Nikiforov
YE
, Carty
SE
, Chiosea
SI
, Coyne
C
, Duvvuri
U
, Ferris
RL
, et al Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology
. Thyroid
. 2015
Nov
;25
(11
):1217
–23
.
[PubMed]
1050-7256110.
Nikiforov
YE
, Carty
SE
, Chiosea
SI
, Coyne
C
, Duvvuri
U
, Ferris
RL
, et al Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay
. Cancer
. 2014
Dec
;120
(23
):3627
–34
.
[PubMed]
0008-543X111.
Parsons
HA
, Beaver
JA
, Cimino-Mathews
A
, Ali
SM
, Axilbund
J
, Chu
D
, et al Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer
. Clin Cancer Res
. 2017
Jan
;23
(2
):379
–86
.
[PubMed]
1078-0432112.
Goodman
AM
, Choi
M
, Wieduwilt
M
, Mulroney
C
, Costello
C
, Frampton
G
, Miller
V
, Kurzrock
R
: Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies.
JCO precision oncology 2017
;1:1-13. © 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
